Quanterix (QTRX) TD Cowen 46th Annual Health Care Conference summary

Leadership vision and strategic direction

• New CEO brings over 30 years of healthcare experience, emphasizing the need for breakthrough technologies in neurology, oncology, and immunology.

• Focus on leveraging a strong base business and recent Akoya acquisition to diversify offerings.

• Strategic review underway to prioritize next-generation platforms and sustainable growth opportunities.

• Commitment to building a robust diagnostics strategy, especially in Alzheimer's, with a comprehensive plan expected in the second half of the year.

• Emphasis on maintaining a solid balance sheet, targeting $84 million in synergies by end of Q1 and cash flow breakeven in the second half of the year.

Financial performance and operational highlights

• Fourth quarter results exceeded expectations, driven by strong consumables demand and recurring revenue now at 75%.

• Margins have rebounded to 30%, and adjusted cash burn reduced to $3 million, down from $15–$20 million per business.

• Akoya acquisition has diversified revenue streams, shifting from 90% neurology to 60% neurology and 40% oncology/immunology.

• Akoya outperformed expectations in Q4, with $36–$37 million revenue versus a $30 million forecast, mainly from consumables.

• Integration efforts are progressing, with a unified company culture and ongoing optimization of technology and service offerings.

Growth outlook and market positioning

• 2026 guidance projects 0–3% growth, primarily from consumables, with high single-digit growth expected in a normalized environment.

• Recurring revenue is targeted to reach 80–85%, with margin improvements anticipated as volumes increase.

• Accelerator Lab serves as a key innovation driver, providing early insights into customer needs and supporting next-gen assay development.

• Pharma project numbers remain stable, though project sizes have been impacted by funding challenges; any increase in pharma spending would be a tailwind.

• International expansion, especially in Asia, is seen as an underappreciated growth area, with key partnerships and certifications in place.